FWD Hong Kong Launches "Renjin Medical Insurance Plan" and Partners with Hong Kong Pharmaceutical Care Foundation

Stock News
Aug 18

FWD Hong Kong announced the launch of its "Renjin Medical Insurance Plan," integrating Environmental, Social, and Governance (ESG) strategies into product design and development to provide flexible and affordable medical coverage for the general public through innovative product concepts. FWD simultaneously announced a partnership with the Hong Kong Pharmaceutical Care Foundation to offer market-first pharmaceutical consultation and management services for "Renjin" insurance and designated medical insurance product customers, further enhancing customers' health management experience.

According to a previous survey by the Hong Kong Census and Statistics Department, more than half of Hong Kong residents do not have personal medical insurance, highlighting a significant medical coverage gap in the market. Relying solely on public hospital coverage may also underestimate out-of-pocket treatment and medication expenses. In response to this situation, FWD launched "Renjin" insurance to fill this coverage gap, targeting self-funded medications and medical services not subsidized by public hospitals, and providing coverage for imaging tests conducted at private medical institutions upon referral, enabling more citizens to access appropriate medical support.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10